Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rainer Oberbauer

Showing results (241-250 of 291) with videos related to

Pageof 30
Sort By:
Kidney International|October 27, 2018
A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal healthAndreas Vychytil, Rebecca Herzog, Paul Probst, et al.
Transplantation|November 30, 2005
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal functionGraeme Russ, Giuseppe Segoloni, Rainer Oberbauer, et al.
BMC Nephrology|September 4, 2019
Next generation sequencing based assessment of the alloreactive T cell receptor repertoire in kidney transplant patients during rejection: a prospective cohort studyConstantin Aschauer, Kira Jelencsics, Karin Hu, et al.
Wiener Klinische Wochenschrift|April 14, 2019
[Diabetic kidney disease (Update 2019) : Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology]Harald Sourij, Roland Edlinger, Friedrich C Prischl, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|June 7, 2022
Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney TransplantationCandice Roufosse, Jan Ulrich Becker, Marion Rabant, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|June 7, 2022
Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney TransplantationDaniel Seron, Marion Rabant, Jan Ulrich Becker, et al.
Journal of Clinical Medicine|October 31, 2020
Impact of Timely Public Health Measures on Kidney Transplantation in Austria during the SARS-CoV-2 Outbreak-A Nationwide AnalysisBruno Watschinger, Clara Watschinger, Roman Reindl-Schwaighofer, et al.
Transplantation|January 22, 2009
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trialFrancesco P Schena, Michael D Pascoe, Josefina Alberu, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 23, 2004
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantationRainer Oberbauer, Giuseppe Segoloni, Josep M Campistol, et al.
Journal of the American Society of Nephrology : JASN|January 26, 2006
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantationJosep M Campistol, Josette Eris, Rainer Oberbauer, et al.
Pageof 30

Showing results (241-250 of 291) with videos related to

Sort By:
Pageof 30
Kidney International|October 27, 2018
A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal healthAndreas Vychytil, Rebecca Herzog, Paul Probst, et al.
Transplantation|November 30, 2005
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal functionGraeme Russ, Giuseppe Segoloni, Rainer Oberbauer, et al.
BMC Nephrology|September 4, 2019
Next generation sequencing based assessment of the alloreactive T cell receptor repertoire in kidney transplant patients during rejection: a prospective cohort studyConstantin Aschauer, Kira Jelencsics, Karin Hu, et al.
Wiener Klinische Wochenschrift|April 14, 2019
[Diabetic kidney disease (Update 2019) : Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology]Harald Sourij, Roland Edlinger, Friedrich C Prischl, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|June 7, 2022
Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney TransplantationCandice Roufosse, Jan Ulrich Becker, Marion Rabant, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|June 7, 2022
Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney TransplantationDaniel Seron, Marion Rabant, Jan Ulrich Becker, et al.
Journal of Clinical Medicine|October 31, 2020
Impact of Timely Public Health Measures on Kidney Transplantation in Austria during the SARS-CoV-2 Outbreak-A Nationwide AnalysisBruno Watschinger, Clara Watschinger, Roman Reindl-Schwaighofer, et al.
Transplantation|January 22, 2009
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trialFrancesco P Schena, Michael D Pascoe, Josefina Alberu, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 23, 2004
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantationRainer Oberbauer, Giuseppe Segoloni, Josep M Campistol, et al.
Journal of the American Society of Nephrology : JASN|January 26, 2006
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantationJosep M Campistol, Josette Eris, Rainer Oberbauer, et al.
Pageof 30